Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen

This observational study is following women with breast cancer who receive a chemotherapy drug called liposomal doxorubicin as part of their treatment after surgery. Researchers want to track how well the treatment works and what side effects occur in real-world practice. **You may be eligible if...** - You are a woman aged 18–75 - You have been diagnosed with primary breast cancer confirmed by biopsy - Your adjuvant (post-surgery) chemotherapy plan includes liposomal doxorubicin - Your heart is functioning well (ejection fraction of 55% or higher) - Your estimated survival is at least 6 months **You may NOT be eligible if...** - You have significant heart, liver, kidney, or bone marrow problems - You are pregnant or breastfeeding - You have had a prior serious reaction to anthracycline chemotherapy drugs Talk to your doctor to see if this trial is right for you.